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Formation of inclusion bodies in bacterial hosts poses a major challenge for large scale recovery of bioactive
proteins. The process of obtaining bioactive protein from inclusion bodies is labor intensive and the yields of
recombinant protein are often low. Here we review the developments in the field that are targeted at improving
the yield, as well as quality of the recombinant protein by optimizing the individual steps of the process, especially
solubilization of the inclusion bodies and refolding of the solubilized protein. Mild solubilization methods have
been discussed which are based on the understanding of the fact that protein molecules in inclusion body
aggregates have native-like structure. These methods solubilize the inclusion body aggregates while preserving the
native-like protein structure. Subsequent protein refolding and purification results in high recovery of bioactive
protein. Other parameters which influence the overall recovery of bioactive protein from inclusion bodies have also
been discussed. A schematic model describing the utility of mild solubilization methods for high throughput
recovery of bioactive protein has also been presented.
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High level expression of recombinant protein in Escheri-
chia coli often results in aggregation of the expressed pro-
tein molecules into inclusion bodies [1-3]. Use of high
temperature during protein expression, high inducer con-
centration and expression under strong promoter systems
often results in expression of the desired protein at a high
translational rate. This exhausts bacterial protein quality
control system and the partially folded and misfolded pro-
tein molecules aggregate to form inclusion bodies [4]. Re-
duced environment of bacterial cytosol, lack of eukaryotic
chaperones and post-translational machinery also contrib-
ute to the formation of inclusion bodies [5]. Although in
recent years bacterial inclusion bodies have been reported
to provide many biotechnological applications [6], the em-
phasis of this current review is to elaborate upon the re-
covery of recombinant proteins from inclusion bodies
particularly using mild solubilization processes.
Formation of inclusion bodies imposes a great hurdle in
production and purification of recombinant proteins using
E. coli as host [7-9]. Inclusion bodies need extensive* Correspondence: amulya@nii.res.in
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unless otherwise stated.processing involving isolation from cell, solubilization,
refolding and purification to produce the bioactive proteins.
In spite of new developments in understanding of the
structural details of protein in inclusion bodies, most of the
times, solubilization and refolding is carried out in empir-
ical ways leading to poor recovery of functional protein.
Solubilization of inclusion body proteins and their refolding
can be fine tuned in accordance with the new information
about the structural and functional characteristics of inclu-
sion body proteins. In E. coli due to specificity of protein
aggregation, inclusion bodies mostly consist of the target
recombinant protein of interest. If a convenient and effi-
cient way of recovering properly folded protein molecules
from inclusion body aggregates can be developed, it will re-
duce the need of extensive chromatographic purification
steps. Inclusion bodies have been shown to have protein
molecules in native-like conformation with some inclusion
bodies having significant biological activity. Use of high
concentration of chaotropes like urea and guanidine hydro-
chloride (GdnHCl) results in complete denaturation of
these existing secondary structures and often leads to ag-
gregation of protein molecules during refolding process.
Recovery and refolding of protein from inclusion bodies
using mild solubilization strategies have been reported tohis is an Open Access article distributed under the terms of the Creative
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Singh et al. Microbial Cell Factories  (2015) 14:41 Page 2 of 10be high in comparison to that achieved while solubilizing
with high concentration of chaotropes. These mild
solubilization agents retain the existing secondary struc-
tures of proteins to some extent; inhibit protein aggrega-
tion during refolding leading to improved recovery of
bioactive proteins. The objective of the present review is
to update the recent findings on structural features of pro-
teins in inclusion bodies and new developments in mild
solubilization processes for high-throughput recovery of
bioactive protein from inclusion bodies of E. coli.
Factors affecting formation of inclusion bodies in E. coli
Multiple factors contribute towards the formation of
protein aggregates as inclusion bodies. In E. coli, inclu-
sion bodies accumulate intracellularly as refractile particles
with a typical size range of 0.2 to 1.5 μm [10]. Under elec-
tron microscope, they appear to be dense, refractile parti-
cles with smooth or rough surface morphology [5]. In
general, inclusion bodies are spherical but can take cylin-
drical to ovoid shape to fit the bacterial cell [11]. In E. coli
they are mostly found to be localized at one or both the
poles of bacterial cells [12]. It has been recently reported
that localization of inclusion body at the poles of bacterial
cell is driven by macromolecular crowding in bacterial
cytosol [13]. During cell division only one daughter cell re-
ceives the inclusion body and formation of inclusion body
in the other cell starts de novo [12]. Generally inclusion
bodies are accumulated in cytosol, but proteins with secre-
tary signals have also been reported to form aggregates in
periplasmic space [14,15].
Expression of recombinant proteins involves multiple
synthetic pathways and is regulated at transcriptional
and translational levels. Usually, when the level of ex-
pression of protein goes beyond 2% of the total cellular
proteins, it leads to inclusion body formation [16]. Fac-
tors which favor high rate of recombinant protein ex-
pression increase the chances of the expressed protein
to get aggregated into inclusion bodies. High copy num-
ber of target gene, strong promoter system and high in-
ducer concentration favor the formation of inclusion
bodies. Too high a copy number costs the cells a high
metabolic burden while a low copy number puts forth a
risk of plasmid loss in subsequent generations. The pro-
moter strength of the vectors also plays an important
role in regulating the expression levels of the proteins.
When bacterial cells having a strong promoter system
are induced to produce recombinant proteins, they ex-
perience an elevated level of metabolic burden with in-
creased chances of expressed recombinant protein to
aggregate into inclusion bodies [17,18]. Reduced envir-
onment of bacterial cytosol also causes protein aggrega-
tion [19]. Formation of inclusion bodies also depends
upon amino acid sequence of protein with highly hydro-
phobic proteins having more chances to aggregate intoinclusion bodies [16]. Presence of bacterial chaperones
has been widely reported in inclusion bodies [4,20]. It has
been shown that absence of cytosolic chaperone, ClpB in-
creases insoluble expression of aggregation prone recom-
binant proteins [20]. Protein aggregation is a regulated
phenomenon in most type of cells [21]. In E. coli, these ag-
gregates in the form of inclusion bodies are deposited at
poles only [12]. This polar localization result in partition
of inclusion bodies in an asymmetric way between the
daughter cells [22]. This helps in enhanced cell growth
rate of the daughter cells devoid of aggregates and make
the bacteria better suited for further division.
Structural features of proteins in inclusion bodies
The first detailed mechanistic studies on formation of
inclusion bodies were conducted by King and colleagues
[23]. In vitro folding of phage P22 tailspike protein was
compared with in vivo folding pathway. This lead to the
development of a model describing partitioning of poly-
peptides into folding and aggregation pathways from
partially folded intermediate [23]. It is widely accepted
that protein aggregation is a highly specific process and
protein molecules can only aggregate with other mole-
cules of same or highly related proteins. Inclusion body
aggregates are also highly specific in nature as recombin-
ant protein constitutes major fraction of these aggre-
gates. Kopito and co-workers in 2001, employing two
different aggregation prone proteins labeled with differ-
ent fluorescent protein tags, showed using fluorescence
resonance energy transfer (FRET) that these proteins do
not co-aggregate in eukaryotic cell [24]. Specificity of
protein aggregation in bacterial inclusion bodies was fur-
ther confirmed by expressing amyloid beta with two differ-
ent fluorescent tags [Blue Fluorescent Protein (BFP) and
Green Fluorescent Protein (GFP)], followed by FRET ana-
lysis [25]. It was observed that same type of protein mole-
cules co-aggregate in cell whereas different proteins like
VP1 do not co-aggregate with amyloid beta [25]. These re-
sults showed that protein aggregation in inclusion bodies is
a highly specific phenomenon.
Inclusion bodies are highly dynamic in nature and pro-
tein molecules participating in inclusion body formation
can reversibly disaggregate and fold into their native form
[26,27]. There exists a dynamic equilibrium between pro-
tein molecules aggregated in inclusion bodies and their
soluble counterpart. Thus, a continuous process of con-
struction and deconstruction of inclusion bodies takes
place in which protein molecules in aggregated and sol-
uble forms can freely exchange their localization [26].
Classically, inclusion bodies were considered to be
amorphous type of aggregates, devoid of any structural
regularity. In last decade, a number of reports provided
evidences in support of amyloid nature of inclusion bod-
ies [28], though recently it was shown that there can be
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Inclusion body aggregates have been shown to bind to
amyloid specific dyes such as Thioflavin T and Congo Red
[28]. Fourier transform infrared (FTIR) spectroscopic ana-
lysis reveals that inclusion bodies are rich in beta content
and give signals corresponding to cross-beta structure, a
characteristic feature of amyloid aggregation [30]. Presence
of cross-beta structure in these aggregates is also evident
from the X-Ray diffraction pattern given by inclusion bod-
ies which has striking similarity to that generated by amyl-
oid fibrils [31]. Amyloid aggregation is a nucleation based
phenomenon and aggregates of a protein can act as seeds
for aggregation of similar proteins. This also holds true for
E. coli inclusion bodies. It has been reported that like amyl-
oid aggregates, inclusion bodies can seed in vitro aggrega-
tion of similar proteins [25]. Inclusion bodies incubated
with soluble protein have been shown to be associated with
long fibrillar structures having morphological similarity
with amyloid fibrils [25]. It has also been reported using H/
D exchange NMR that amyloid formation in inclusion body
aggregates is a residue specific phenomenon [31]. Even a
point mutation can inhibit the process of inclusion body
formation [15,32]. There are several online servers which
predict regions which have high propensity to form amy-
loids. Hamodrakas and co-workers have recently applied
such a tool to predict polypeptide regions which are re-
sponsible for the formation of inclusion bodies [33].
Bacterial inclusion bodies have been reported to have
native-like secondary structures [27]. Proteins like
Interleukin-1β, β-lactamase, Human granulocyte-colony
stimulating factor (GCSF) form inclusion bodies having
native-like secondary structure [27,34,35]. Initial studies
reporting presence of native-like secondary structures
primarily used FTIR spectroscopy [34]. Solid state NMR
spectroscopy has also been used to demonstrate the
presence of native-like structure in inclusion bodies
[36]. Moreover, a large number of inclusion bodies have
been shown to have considerable biological activity
[37,38]. Although the first report suggesting presence of
activity in inclusion bodies came in 1989 [39], it is in
the last decade that active inclusion bodies have
grabbed the attention due to their potential applications
in various processes [40-45]. Inclusion bodies of β-
lactamase, β-galactosidase, and GCSF have been shown
to have considerable biological activity [27]. Inclusion
body aggregates which are biologically active are known
as non-classical inclusion bodies [46]. Most of the non-
classical inclusion bodies are characterized by a loose ar-
rangement of protein molecules and thus can be solubilized
even at low concentration of denaturants [47]. The propor-
tion of active molecules inside inclusion bodies depends
upon physical conditions used during protein expression.
Quality of inclusion bodies can be modulated by changing
expression temperature. Although formation of activeinclusion bodies at high temperature has also been reported
[41], it is generally considered that low expression
temperature favors the formation of non-classical inclusion
bodies [46,48].
Formation of active inclusion bodies can be induced
by linking a protein to aggregation prone peptides by
suitable linkers. Wu et al. demonstrated that linking a
self-assembling ionic peptide ELK16 (LELELKLK)2 to
proteins can lead to formation of inclusion bodies with
significant biological activity [49]. Surfactant like pep-
tides have also been used to form biologically active in-
clusion bodies [50]. Attachment of full length green
fluorescent protein as an inducer of aggregation for the
formation of active inclusion bodies and importance of
the linker peptides has also been reported [51].
Inclusion body aggregates are of highly dynamic na-
ture. Besides the recombinant protein, inclusion bodies
also contain components from bacterial membrane,
other host proteins and RNA [52]. As mentioned earlier,
inclusion bodies contain amyloid-like proto-fibrils or fi-
brils. Riek and coworkers using NMR spectroscopy have
shown that a fraction of proteins in inclusion bodies
have H/D exchange rates different than those of amyloid
content [31]. This indicated that there exists a structural
heterogeneity in inclusion bodies. This heterogeneity can
be due to contaminating host proteins. There is also a
possibility that recombinant protein molecules in un-
folded, partially folded or even native structures can co-
exist in inclusion bodies and in part are responsible for
the structural heterogeneity of protein aggregates in in-
clusion bodies. This also provides an explanation for the
presence of activity in some inclusion bodies. The
current theoretical model of inclusion bodies assumes
that they are primarily made up of amyloid-like proto-
aggregates. Recombinant protein molecules in other
conformations, including the native state, are trapped in
the network of amyloid-like proto-fibrils or fibrils [11].
The proportions of amyloid-like component and other
structural forms of recombinant protein depend upon a
number of factors including the physical conditions used
during expression [53]. All these new information
strongly suggest that inclusion body proteins have con-
siderable amount of native-like structures.
Recovery of bioactive proteins from inclusion bodies
As protein molecules are in an aggregated state in inclu-
sion bodies, it is a challenging task to solubilize inclusion
bodies and refold the solubilized proteins into bioactive
form [8,9,54]. The conventional strategy to purify proteins
from inclusion bodies consists of four major steps: isola-
tion of purified inclusion bodies, solubilization of inclusion
bodies, refolding of solubilized proteins and purification of
refolded proteins by various chromatographic techniques
[55]. Solubilization of inclusion bodies and refolding of
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the most crucial steps in the recovery of bioactive protein
from inclusion bodies.
Isolation of purified inclusion bodies from E. coli cells
Inclusion bodies are highly specific aggregates and are
mostly composed of recombinant protein of interest. It is
thus necessary to isolate and purify inclusion body aggre-
gates into homogeneity before solubilization and refolding.
Purification of proteins from inclusion bodies reduces the
need of tags and multiple chromatographic steps. As dis-
cussed above, expression conditions affect the quality of in-
clusion bodies. Low expression temperatures can help in
formation of soft, non-classical inclusion bodies which can
be solubilized using non-denaturing solvents [46,48]. Regu-
lating the pH during expression has been reported to affect
inclusion body quality [56]. Methods used for the isolation
of inclusion bodies from bacterial cells include mechanical
cell rupture using sonication or French press and chemical
cell disruption methods which make use of cell lysis agents
like lysozyme. The choice of cell disruption method has
been reported to make a great impact on quality of inclu-
sion bodies [47]. Cell disruption by chemical methods is
supposed to be better in comparison to the mechanical
methods like sonication or homogenization. The latter
affect the quality of inclusion bodies and lead to aggrega-
tion of protein molecules which were initially a part of sol-
uble fraction [47]. Use of suitable combination of
mechanical and chemical cell disruption techniques have
also been reported [57]. Inclusion bodies, due to their high
density in comparison to other cellular components can be
isolated from the whole cell lysate by centrifugation [57].
Cross-flow membrane microfiltration has also been used
for isolating inclusion bodies from host cellular proteins
[58]. Isolated inclusion bodies contain several impurities
like host proteins, RNA and host membrane fragments
[52]. They are further purified using several washing steps.
Washing with low concentrations of detergents like deoxy-
cholic acid and Triton X-100 [54] not only helps in achiev-
ing highly purified inclusion bodies, but also helps in
removing membrane fragments. Non-classical inclusion
bodies have been reported to be very sensitive to pH at
which they are purified, as use of high pH can lead to
solubilization of protein molecules during purification
[53,57]. Sucrose density gradient ultracentrifugation has
also been used for purification of inclusion bodies [57].
Pure inclusion bodies help in reducing the interference of
contaminants during refolding process and reduce the re-
quirement of extensive purification steps.
Solubilization of inclusion body proteins
Traditionally, inclusion bodies are solubilized using high
concentration of denaturants and chaotropes like urea and
guanidine hydrochloride (GdnHCl) [8,59]. For proteinscontaining multiple cysteine residues, β-mercaptoethanol
or dithiothreitol are added in these solubilization agents to
reduce incorrect disulfide bonds. Solubilization of inclusion
bodies using high concentration of chaotropes results in
complete disruption of protein structure. This, in some
cases, leads to aggregation of protein molecules during
refolding process [60]. As inclusion body aggregates have
been shown to have native-like secondary structures and
can have activity, it is advantageous to use a “mild”
solubilization process which does not completely unfold
these native-like protein structures [61].
As mentioned earlier, inclusion bodies are dynamic in
nature and there exists an equilibrium between folded and
aggregated protein molecules. This fact can be utilized for
solubilizing inclusion bodies in non-denaturing buffers
without assistance of any solubilization agent. Inclusion
bodies of N-acetyl-d-glucosamine 2-epimerase have been
solubilized using Tris–HCl buffer at pH 7. The solubilized
protein was reported to be active [62]. Biologically active
protein molecules can be extracted from non-classical in-
clusion bodies using mild solubilization conditions. This
process preserve the native-like protein structures present
in inclusion bodies and thus bypasses the refolding steps.
Low concentrations of organic solvents like 5% n-
propanol and DMSO and detergents like 0.2% N-lauroyl
sarcosine has been used as mild solubilization agents for
solubilization of non-classical inclusion bodies [46]. Low
concentration of urea in many cases has also been used to
solubilize inclusion body aggregates [46,63]. These
solubilization agents result into extraction of active re-
combinant protein without any requirement of refolding
step. The major drawback of these methods is their limita-
tion to work on classical inclusion bodies.
For efficient solubilization of inclusion bodies, several
mild solubilization methods have been developed which
keep the protein molecules in partially folded state dur-
ing solubilization. With these methods, refolding of solu-
bilized protein molecules starts from a partially folded
form, inhibiting the molecules from going into aggrega-
tion pathway during refolding. The schematic diagram
representing these mild solubilization methods is given
in Figure 1. Mild solubilization processes using alkaline
pH [19,61], high pressure [64], detergents [65,66], or-
ganic solvents [60] and low concentration of chaotropes
[46,63] have been used for recovery of bioactive proteins
from inclusion bodies. Table 1 provides the summary of
these methods. In most of the cases, improvements in
inclusion body isolation and use of modern refolding
methods in combination with mild solubilization im-
proved the overall recovery of bioactive proteins.
High hydrostatic pressure also helps in solubilization of
inclusion body aggregates [64]. High pressure (2–4 kbar)
disrupts the intermolecular interactions and disaggregates
inclusion bodies. Removal of applied high pressure leads to
Figure 1 Model showing different solubilization methods used for recovery of protein from inclusion bodies.
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clusion bodies applying 2.4 kbar pressures at −9°C and
subsequent refolding at 0.4 kbar and 20°C has also been
shown to improve refolding of recombinant endostatin
[68].
Use of buffers with extreme pH has also been reported as
a mild solubilization method. High pH (>12) buffer in com-
bination with 2 M urea has been used successfully for
solubilization of inclusion bodies [19,61]. High pH buffer
has been described to improve refolding yield by retaining
native-like secondary structures in solubilized state [19].
Solubilization with low concentrations of urea [63], deter-
gents like N-Lauroylsarcosine and Lauroyl-L-glutamate
have also been reported to improve the yield of bioactive
protein from inclusion bodies [65,66,69].
Use of organic solvents like β-mercaptoethanol (βME)
[70] and n-propanol in combination with low concentra-
tion of urea has been reported as a novel solubilization
strategy for improved recovery of proteins [60]. Both the
solvents have been used to solubilize human growthhormone inclusion bodies. In case of human growth hor-
mone, use of n-propanol based buffer enhances refolding
yield over the conventionally used urea or GdnHCl based
buffers by preserving native-like secondary structure [60].
Organic solvents, mainly alcohols have long been known to
be interacting with proteins and affect their secondary and
tertiary structure. Many alcohols have also been shown to
have a stabilizing effect on the protein secondary structure
and are known to induce helicity even in non structured
peptides [71,72]. Solubilization of inclusion body aggregates
using organic solvent thus provides a viable alternative to
urea/GdnHCl based solubilization. A variety of proteins
have been reported to be solubilized by a mixture of n-
propanol and 2 M urea [60]. This opens up new possibil-
ities for the improved recovery of proteins from bacterial
inclusion bodies using organic solvent based solubilization.
No single method of solubilization works for every
protein and thus, screening for solubilization agents for
optimized solubilization has to be carried out. For a fast
and convenient screening of solubilization agents, Hahn
Table 1 Mild solubilization methods used for recovery of proteins from inclusion bodies
Solubilization method Remarks Reference
Tris-Cl buffer, low concentration of DMSO,
n-propanol and Sarcosyl
Non-denaturing solubilization methods for non-classical inclusion
bodies. No need of refolding
[46,62]
Low concentration of urea Mild solubilization, low concentration of urea doesn’t completely denature
solubilized protein molecules
[46,63]
Organic solvent based solubilization High solubilization efficiency, inhibition of aggregation during refolding [60]
High hydrostatic pressure High solubilization efficiency with simultaneous refolding of solubilized protein [64,68]
High pH buffers High pH in combination with low concentration of urea. Mild, efficient solubilization [19,61]
Detergents Mild solubilization [65,66]
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throughput assay to screen a large number of solubilization
agents [73]. Mild solubilization of inclusion body aggregates
by understating the dominant force that cause protein ag-
gregation is thus the key for successful development of high
throughput protein refolding process from inclusion bodies
of E. coli.
Refolding of solubilized protein
Solubilized inclusion body proteins are refolded by re-
moval of solubilization agent. Dilution of the solubilized
protein in refolding buffer [59] and dialysis of the solubi-
lized protein in presence of refolding buffer [74] are the
most common methods used to recover functionally ac-
tive proteins. These methods suffer from disadvantages
like high buffer requirement particularly for large scale
operation and low refolding yields due to protein aggre-
gation. Low protein concentration and reduced intermo-
lecular interactions during refolding are a prerequisite
for inhibiting protein aggregation and increasing the
refolding yield. To achieve this, a modified method for
dilution known as pulsatile dilution has been developed,
which significantly reduces the buffer requirement and
improves the refolding yield of proteins [54].
To improve the quality of the refolded protein and
scale up the process for industrial application, refolding
in packed chromatographic columns has been devel-
oped. Different chromatographic methods have been
used for refolding of solubilized proteins. Size exclusion
[75-79], ion exchange [80-83] and affinity chromatog-
raphy [84-86] are the most extensively used methods,
while hydrophobic interaction chromatography [87,88]
has also been used in some of the cases. On column
refolding, as it is called, has several advantages over con-
ventional methods of dilution and dialysis. Use of size
exclusion chromatography for refolding results in separ-
ation of the folded form from the aggregated and mis-
folded forms during elution with the refolding buffer. In
other chromatographic methods, refolding process oc-
curs after immobilization of the protein on the solid
support that leads to spatial separation of the refolding
units and decreased intermolecular interactions. Thus,refolding processes in chromatographic beds can be car-
ried out at high protein concentrations. Also, the refold-
ing process is coupled with denaturant removal and
purification of the target protein. This decreases the
number of steps involved in the purification procedure
and automates the process [89,90]. There are reports of
using chaperonins immobilized on the chromatographic
media with a view of mimicking in vivo folding [91-95].
Although, an increase in refolding yield is observed, the
industrial application is limited due to high process cost.
Continuous developments in the field have improved the
process and the recent advances in the methods are
aimed at increasing the refolding yield [96] and
optimization of the refolding conditions to improve the
quality of the protein [97].
A new method of refolding has been recently de-
scribed that involves the use of microfluidic chips [98].
In microfluidic chips the denaturant concentration is
maintained by controlling diffusion through laminar flow
in microchannels and has been used for refolding of dif-
ficult to fold protein like citrate synthase. Another
method of protein refolding using urease enzyme has
also been described that involves gradual removal of
urea from the solubilized protein solution mediated by
urease enzyme catalyzed reaction [99]. A major advan-
tage of such a system is that efficient protein refolding
can be achieved in low volume without the use of refold-
ing buffers that can significantly decrease the cost of
production. Different methods used for refolding of sol-
ubilized inclusion body proteins are summarized in
Table 2.
The success of the method employed for refolding de-
pends in part on the composition of refolding buffer.
The most common problem during refolding is the ag-
gregation of the target protein and most of the refolding
strategies involve the use of certain additives in refolding
buffer to inhibit aggregation. Apart from aggregation in-
hibitors, certain folding enhancers are also used to im-
prove the yield. Common additives used in refolding
buffer include chaotropic agents like urea [19] or guan-
idine hydrochloride [74] in low concentrations, amino
acids like glycine [100], arginine [101,102] and proline
Table 2 Methods used for refolding of solubilized inclusion body proteins
Refolding methods Remarks Reference
Dilution
Flash dilution Simplest method [59]
Pulsatile dilution low requirement of buffer and improved refolding yield [54]
Dialysis
One step dialysis May be successful only for those proteins that are soluble in intermediate states [74]
Step wise dialysis Useful for multidomain or disulphide bond containing proteins [74]
On column refolding
Size exclusion chromatography Separation of folded form from intermediates [75-79]
Anion exchange chromatography More advantageous for crude samples [80-83]
Affinity chromatography Limited to cases where the Tag doesn’t interfere with folding [84-86]
Hydrophobic interaction chromatography May substitute for the requirement of additives during refolding [87,88]
Chromatography in presence of chaperones Reduces aggregation by mimicking in vivo scenario [91-95]
Micro fluidic chips May be useful for difficult to fold proteins [98]
Urease mediated refolding No requirement of refolding buffer [99]
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ene glycol [105-108], glycerol [104,109], sorbitol [110]
and sucrose [104]. Non detergent zwitterions like sulfo-
betaines, substituted pyridines and pyrroles and acid
substituted amino cyclohexanes have also been used as
additives during refolding [111-114]. These additives are
summarized in Table 3.
It is known that refolding of some proteins in vivo re-
quire the presence of N-terminal pro-peptide betweenTable 3 List of additives commonly used to promote
refolding of solubilized proteins















Substituted pyridines and pyrolles
Acid substituted aminocyclohexanesthe signal peptide and the mature part of polypeptide
[115]. Some strategies of refolding in vitro exploit the
addition of the pro-peptide in the refolding buffer to in-
crease the refolding yield [116-118]. Similarly, other
strategies inspired from protein folding in vivo exploit
chaperones in refolding of solubilized proteins. Chaper-
ones are natural protein folding aiding machinery. They
act by sequential capture and release of the refolding in-
termediates and preventing them from interacting with
each other. The use of chaperones and other folding cat-
alysts like peptidylprolyl cis-trans isomerase or protein-
disulfide isomerase, that accelerate the rate limiting steps
on the folding pathway, have been shown to improve the
refolding yield [91-95]. Detergent micelles acting as arti-
ficial chaperon systems have been used in improving the
yield of refolding process. Here the protein folding inter-
mediates interact with detergents to form mixed
protein-detergent micelles and are protected from inter-
molecular interactions. The refolding of the intermediate
form is initiated by addition of cyclodextrins that strip
the detergents from the protein-detergent complex by
forming more stable detergent cyclodextrin-complex
[119,120]. Recently, a strategy to purify and refold pro-
teins was described based on separation of the proteins
using affinity ligands bound to smart polymers [121-124].
These polymers precipitate on providing specific stimulus
like temperature, pH or change in ionic strength, thus pre-
cipitating the protein of interest. The bound proteins are
then recovered from the polymers by reversing the pre-
cipitating conditions. There is no universal buffer for opti-
mal protein refolding and the composition of the refolding
buffer has to be screened for each case individually
[9,125-126].
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Advanced structural techniques have significantly en-
hanced our understanding of protein structure in inclu-
sion body aggregates. Inclusion bodies are now considered
to have conformational heterogeneity, with amyloid struc-
tures building a network in which protein molecules with
other conformations, including the native ones, are
trapped. Mild solubilization methods have been developed
in order to preserve these native-like structures and pro-
vide a viable alternative to the conventional use of high
concentration of chaotropes. Efficient recovery of folded
protein also reduces the burden of extensive chromato-
graphic steps. Combined with improved refolding
methods, mild solubilization results in high-throughput
recovery of bioactive proteins from inclusion bodies. The
process of protein recovery from inclusion bodies involves
four steps: 1. Purification of inclusion bodies to homogen-
eity (careful lysis of cells, purify inclusion bodies by deter-
gent washing/ultracentrifugation), 2. Solubilization of
inclusion bodies using mild solubilization agent (alkaline
pH/hydrostatic pressure/organic solvent based buffers/2-
3 M urea/detergents), 3. Refolding of the solubilized pro-
teins (refolding at high protein concentration by pulsatile
renaturation/on column refolding/urease mediated refold-
ing) with optimal refolding buffer and 4. Purification of
the refolded protein. These steps can be optimized to re-
cover high amount of bioactive protein from the inclusion
bodies of E. coli.
Abbreviations
BFP: Blue fluorescent protein; DMSO: Dimethyl sulphoxide; FTIR: Fourier
Transform Infrared; FRET: Fluorescence resonance energy transfer;
GCSF: Granulocyte-colony stimulating factor; GdnHCl: Guanidine
hydrochloride; GFP: Green fluorescent protein; H/D: Hydrogen/Deuterium;
NMR: Nuclear Magnetic Resonance; RNA: Ribose nucleic acid; βME: β-
mercaptoethanol.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed in the development of mild solubilization methods.
AS, VU and AKU prepared the manuscript. All authors read and approved the
final manuscript.
Acknowledgments
The research work was carried out from the core grant of National Institute
of Immunology from Dept. of Biotechnology, Govt. of India.
Received: 15 December 2014 Accepted: 6 March 2015
References
1. Williams DC, Van Frank RM, Muth WL, Burnett JP. Cytoplasmic inclusion
bodies in Escherichia coli producing biosynthetic human insulin proteins.
Science. 1982;215:687–9.
2. Freedman RB, Wetzel R. Protein engineering. Curr Opin Biotechnol.
1992;3:323–5.
3. Chrunyk BA, Evans J, Lillquist J, Young P, Wetzel R. Inclusion body formation
and protein stability in sequence variants of interleukin-1 beta. J Biol Chem.
1993;268:18053–61.4. Carrio MM, Villaverde A. Localization of chaperones DnaK and GroEL in
bacterial inclusion bodies. J Bacteriol. 2005;187:3599–601.
5. Carrio MM, Cubarsi R, Villaverde A. Fine architecture of bacterial inclusion
bodies. FEBS Lett. 2000;471:7–11.
6. Ramon A, Senorale-Pose M, Marin M. Inclusion bodies: not that bad…. Front
Microbiol. 2014;5:56.
7. Marston FA. The purification of eukaryotic polypeptides synthesized in
Escherichia coli. Biochem J. 1986;240:1–12.
8. Rudolph R, Lilie H. In vitro folding of inclusion body proteins. FASEB J.
1996;10:49–56.
9. Burgess RR. Refolding solubilized inclusion body proteins. Methods Enzymol.
2009;463:259–82.
10. Taylor G, Hoare M, Gray DR, Marston FAO. Size and density of protein
inclusion bodies. Nat Biotechnol. 1986;4:553–7.
11. Peternel S, Komel R. Active protein aggregates produced in Escherichia coli.
Int J Mol Sci. 2011;12:8275–87.
12. Lindner AB, Madden R, Demarez A, Stewart EJ, Taddei F. Asymmetric
segregation of protein aggregates is associated with cellular aging and
rejuvenation. Proc Natl Acad Sci U S A. 2008;105:3076–81.
13. Coquel AS, Jacob JP, Primet M, Demarez A, Dimiccoli M, Julou T, et al.
Localization of protein aggregation in Escherichia coli is governed by
diffusion and nucleoid macromolecular crowding effect. PLoS Comput Biol.
2013;9:e1003038.
14. Arie JP, Miot M, Sassoon N, Betton JM. Formation of active inclusion bodies
in the periplasm of Escherichia coli. Mol Microbiol. 2006;62:427–37.
15. Chan W, Helms LR, Brooks I, Lee G, Ngola S, McNulty D, et al. Mutational
effects on inclusion body formation in the periplasmic expression of the
immunoglobulin VL domain REI. Fold Des. 1996;1:77–89.
16. Mitraki A, Fane B, Haase-Pettingell C, Sturtevant J, King J. Global suppression of
protein folding defects and inclusion body formation. Science. 1991;253:54–8.
17. Allen SP, Polazzi JO, Gierse JK, Easton AM. Two novel heat shock genes
encoding proteins produced in response to heterologous protein
expression in Escherichia coli. J Bacteriol. 1992;174:6938–47.
18. Bukau B. Regulation of the Escherichia coli heat-shock response. Mol Microbiol.
1993;9:671–80.
19. Singh SM, Panda AK. Solubilization and refolding of bacterial inclusion body
proteins. J Biosci Bioeng. 2005;99:303–10.
20. Guenther I, Zolkiewski M, Kedzierska-Mieszkowska S. Cooperation between two
ClpB isoforms enhances the recovery of the recombinant beta-galactosidase
from inclusion bodies. Biochem Biophys Res Commun. 2012;426:596–600.
21. Tyedmers J, Mogk A, Bukau B. Cellular strategies for controlling protein
aggregation. Nat Rev Mol Cell Biol. 2010;11:777–88.
22. Winkler J, Seybert A, Konig L, Pruggnaller S, Haselmann U, Sourjik V, et al.
Quantitative and spatio-temporal features of protein aggregation in Escherichia
coli and consequences on protein quality control and cellular ageing. EMBO J.
2010;29:910–23.
23. Betts S, King J. There’s a right way and a wrong way: in vivo and in vitro folding,
misfolding and subunit assembly of the P22 tailspike. Structure. 1999;7:R131–9.
24. Rajan RS, Illing ME, Bence NF, Kopito RR. Specificity in intracellular protein
aggregation and inclusion body formation. Proc Natl Acad Sci U S A.
2001;98:13060–5.
25. Morell M, Bravo R, Espargaro A, Sisquella X, Aviles FX, Fernandez-Busquets X, et al.
Inclusion bodies: specificity in their aggregation process and amyloid-like
structure. Biochim Biophys Acta. 2008;1783:1815–25.
26. Carrio MM, Villaverde A. Construction and deconstruction of bacterial
inclusion bodies. J Biotechnol. 2002;96:3–12.
27. Ventura S, Villaverde A. Protein quality in bacterial inclusion bodies. Trends
Biotechnol. 2006;24:179–85.
28. de Groot NS, Sabate R, Ventura S. Amyloids in bacterial inclusion bodies.
Trends Biochem Sci. 2009;34:408–16.
29. Capitini C, Conti S, Perni M, Guidi F, Cascella R, De PA, et al. TDP-43 inclusion
bodies formed in bacteria are structurally amorphous, non-amyloid and
inherently toxic to neuroblastoma cells. PLoS One. 2014;9:e86720.
30. Carrio M, Gonzalez-Montalban N, Vera A, Villaverde A, Ventura S. Amyloid-like
properties of bacterial inclusion bodies. J Mol Biol. 2005;347:1025–37.
31. Wang L, Maji SK, Sawaya MR, Eisenberg D, Riek R. Bacterial inclusion bodies
contain amyloid-like structure. PLoS Biol. 2008;6:e195.
32. Nieba L, Honegger A, Krebber C, Pluckthun A. Disrupting the hydrophobic
patches at the antibody variable/constant domain interface: improved
in vivo folding and physical characterization of an engineered scFv
fragment. Protein Eng. 1997;10:435–44.
Singh et al. Microbial Cell Factories  (2015) 14:41 Page 9 of 1033. Tsolis AC, Papandreou NC, Iconomidou VA, Hamodrakas SJ. A consensus
method for the prediction of ‘aggregation-prone’ peptides in globular
proteins. PLoS One. 2013;8:e54175.
34. Przybycien TM, Dunn JP, Valax P, Georgiou G. Secondary structure
characterization of beta-lactamase inclusion bodies. Protein Eng.
1994;7:131–6.
35. Oberg K, Chrunyk BA, Wetzel R, Fink AL. Nativelike secondary structure in
interleukin-1 beta inclusion bodies by attenuated total reflectance FTIR.
Biochemistry. 1994;33:2628–34.
36. Curtis-Fisk J, Spencer RM, Weliky DP. Native conformation at specific
residues in recombinant inclusion body protein in whole cells determined
with solid-state NMR spectroscopy. J Am Chem Soc. 2008;130:12568–9.
37. Garcia-Fruitos E, Gonzalez-Montalban N, Morell M, Vera A, Ferraz RM, Aris A,
et al. Aggregation as bacterial inclusion bodies does not imply inactivation
of enzymes and fluorescent proteins. Microb Cell Fact. 2005;4:27.
38. Garcia-Fruitos E, Aris A, Villaverde A. Localization of functional polypeptides
in bacterial inclusion bodies. Appl Environ Microbiol. 2007;73:289–94.
39. Worrall DM, Goss NH. The formation of biologically active beta-galactosidase
inclusion bodies in Escherichia coli. Aust J Biotechnol. 1989;3:28–32.
40. Roessl U, Nahalka J, Nidetzky B. Carrier-free immobilized enzymes for
biocatalysis. Biotechnol Lett. 2010;32:341–50.
41. Carvajal P, Gibert J, Campos N, Lopera O, Barbera E, Torne JM, et al. Activity
of maize transglutaminase overexpressed in Escherichia coli inclusion bodies:
an alternative to protein refolding. Biotechnol Prog. 2011;27:232–40.
42. Gatti-Lafranconi P, Natalello A, Ami D, Doglia SM, Lotti M. Concepts and
tools to exploit the potential of bacterial inclusion bodies in protein science
and biotechnology. FEBS J. 2011;278:2408–18.
43. Garcia-Fruitos E, Vazquez E, Diez-Gil C, Corchero JL, Seras-Franzoso J, Ratera I,
et al. Bacterial inclusion bodies: making gold from waste. Trends Biotechnol.
2012;30:65–70.
44. Villaverde A, Garcia-Fruitos E, Rinas U, Seras-Franzoso J, Kosoy A, Corchero JL,
et al. Packaging protein drugs as bacterial inclusion bodies for therapeutic
applications. Microb Cell Fact. 2012;11:76.
45. Seras-Franzoso J, Peebo K, Luis CJ, Tsimbouri PM, Unzueta U, Rinas U, et al.
A nanostructured bacterial bioscaffold for the sustained bottom-up delivery
of protein drugs. Nanomedicine (Lond). 2013;8:1587–99.
46. Jevsevar S, Gaberc-Porekar V, Fonda I, Podobnik B, Grdadolnik J, Menart V.
Production of nonclassical inclusion bodies from which correctly folded
protein can be extracted. Biotechnol Prog. 2005;21:632–9.
47. Peternel S, Komel R. Isolation of biologically active nanomaterial (inclusion
bodies) from bacterial cells. Microb Cell Fact. 2010;9:66.
48. Peternel S, Grdadolnik J, Gaberc-Porekar V, Komel R. Engineering inclusion
bodies for non denaturing extraction of functional proteins. Microb Cell
Fact. 2008;7:34.
49. Wu W, Xing L, Zhou B, Lin Z. Active protein aggregates induced by
terminally attached self-assembling peptide ELK16 in Escherichia coli. Microb
Cell Fact. 2011;10:9.
50. Zhou B, Xing L, Wu W, Zhang XE, Lin Z. Small surfactant-like peptides can
drive soluble proteins into active aggregates. Microb Cell Fact. 2012;11:10.
51. Huang Z, Zhang C, Chen S, Ye F, Xing XH. Active inclusion bodies of acid
phosphatase PhoC: aggregation induced by GFP fusion and activities
modulated by linker flexibility. Microb Cell Fact. 2013;12:25.
52. Wang L. Towards revealing the structure of bacterial inclusion bodies. Prion.
2009;3:139–45.
53. Ami D, Natalello A, Gatti-Lafranconi P, Lotti M, Doglia SM. Kinetics of inclusion
body formation studied in intact cells by FT-IR spectroscopy. FEBS Lett.
2005;579:3433–6.
54. Patra AK, Mukhopadhyay R, Mukhija R, Krishnan A, Garg LC, Panda AK.
Optimization of inclusion body solubilization and renaturation of recombinant
human growth hormone from Escherichia coli. Protein Expr Purif. 2000;18:182–92.
55. Clark ED. Protein refolding for industrial processes. Curr Opin Biotechnol.
2001;12:202–7.
56. Castellanos-Mendoza A, Castro-Acosta RM, Olvera A, Zavala G, Mendoza-Vera M,
Garcia-Hernandez E, et al. Influence of pH control in the formation of inclusion
bodies during production of recombinant sphingomyelinase-D in Escherichia coli.
Microb Cell Fact. 2014;13:137.
57. Upadhyay AK, Murmu A, Singh A, Panda AK. Kinetics of inclusion body
formation and its correlation with the characteristics of protein aggregates
in Escherichia coli. PLoS One. 2012;7:e33951.
58. Venkiteshwaran A, Heider P, Matosevic S, Bogsnes A, Staby A, Sharfstein S,
et al. Optimized removal of soluble host cell proteins for the recovery ofmet-human growth hormone inclusion bodies from Escherichia coli cell lysate
using crossflow microfiltration. Biotechnol Prog. 2007;23:667–72.
59. Fischer B, Perry B, Sumner I, Goodenough P. A novel sequential procedure
to enhance the renaturation of recombinant protein from Escherichia coli
inclusion bodies. Protein Eng. 1992;5:593–6.
60. Singh SM, Sharma A, Upadhyay AK, Singh A, Garg LC, Panda AK.
Solubilization of inclusion body proteins using n-propanol and its refolding
into bioactive form. Protein Expr Purif. 2012;81:75–82.
61. Khan RH, Rao KB, Eshwari AN, Totey SM, Panda AK. Solubilization of recombinant
ovine growth hormone with retention of native-like secondary structure and its
refolding from the inclusion bodies of Escherichia coli. Biotechnol Prog.
1998;14:722–8.
62. Lu SC, Lin SC. Recovery of active N-acetyl-D-glucosamine 2-epimerase from
inclusion bodies by solubilization with non-denaturing buffers. Enzyme
Microb Technol. 2012;50:65–70.
63. Upadhyay AK, Singh A, Mukherjee KJ, Panda AK. Refolding and purification
of recombinant L-asparaginase from inclusion bodies of E. coli into active
tetrameric protein. Front Microbiol. 2014;5:486.
64. St John RJ, Carpenter JF, Randolph TW. High pressure fosters protein
refolding from aggregates at high concentrations. Proc Natl Acad Sci U S A.
1999;96:13029–33.
65. Burgess RR. Purification of overproduced Escherichia coli RNA polymerase
sigma factors by solubilizing inclusion bodies and refolding from Sarkosyl.
Methods Enzymol. 1996;273:145–9.
66. Kudou M, Ejima D, Sato H, Yumioka R, Arakawa T, Tsumoto K. Refolding single-
chain antibody (scFv) using lauroyl-L-glutamate as a solubilization detergent and
arginine as a refolding additive. Protein Expr Purif. 2011;77:68–74.
67. Lemke LS, Chura-Chambi RM, Rodrigues D, Cussiol JRR, Malavasi NV, Alegria TGP,
et al. Investigation on solubilization protocols in the refolding of the thioredoxin
TsnC from Xylella fastidiosa by high hydrostatic pressure approach. Protein Expr
Purif. 2015;106:72–7.
68. Chura-Chambi RM, Cordeiro Y, Malavasi NV, Lemke LS, Rodrigues D,
Morganti L. An analysis of the factors that affect the dissociation of
inclusion bodies and the refolding of endostatin under high pressure.
Process Biochem. 2013;48:250–9.
69. Kudou M, Yumioka R, Ejima D, Arakawa T, Tsumoto K. A novel protein
refolding system using lauroyl-l-glutamate as a solubilizing detergent and
arginine as a folding assisting agent. Protein Expr Purif. 2011;75:46–54.
70. Panda AK, Sheikh MG, Eshwari AN, Garg LC. Process for solubilization of
recombinant proteins expressed as inclusion body. 2007. USPTO 7189811
B2.
71. Buck M, Radford SE, Dobson CM. A partially folded state of hen egg white
lysozyme in trifluoroethanol: structural characterization and implications for
protein folding. Biochemistry. 1993;32:669–78.
72. Perham M, Liao J, Wittung-Stafshede P. Differential effects of alcohols on
conformational switchovers in alpha-helical and beta-sheet protein models.
Biochemistry. 2006;45:7740–9.
73. Durauer A, Mayer S, Sprinzl W, Jungbauer A, Hahn R. High-throughput system for
determining dissolution kinetics of inclusion bodies. Biotechnol J. 2009;4:722–9.
74. Tsumoto K, Ejima D, Kumagai I, Arakawa T. Practical considerations in
refolding proteins from inclusion bodies. Protein Expr Purif. 2003;28:1–8.
75. Werner MH, Clore GM, Gronenborn AM, Kondoh A, Fisher RJ. Refolding
proteins by gel filtration chromatography. FEBS Lett. 1994;345:125–30.
76. Batas B, Chaudhuri JB. Protein refolding at high concentration using
size-exclusion chromatography. Biotechnol Bioeng. 1996;50:16–23.
77. Schlegl R, Iberer G, Machold C, Necina R, Jungbauer A. Continuous
matrix-assisted refolding of proteins. J Chromatogr A. 2003;1009:119–32.
78. Gu Z, Weidenhaupt M, Ivanova N, Pavlov M, Xu B, Su ZG, et al.
Chromatographic methods for the isolation of, and refolding of proteins
from, Escherichia coli inclusion bodies. Protein Expr Purif. 2002;25:174–9.
79. Lanckriet H, Middelberg AP. Continuous chromatographic protein refolding.
J Chromatogr A. 2004;1022:103–13.
80. Creighton TE. Folding of proteins adsorbed reversibly to ion-exchange
resins. In: Oxender DL, editor. UCLA Symposia on Molecular and Cellular
Biology, New Series. Volume 39. New York: Alan R. Liss; 1986. p. 249–57.
81. Suttnar J, Dyr JE, Hamsikova E, Novak J, Vonka V. Procedure for refolding
and purification of recombinant proteins from Escherichia coli inclusion
bodies using a strong anion exchanger. J Chromatogr B Biomed Appl.
1994;656:123–6.
82. Li M, Zhang G, Su Z. Dual gradient ion-exchange chromatography improved
refolding yield of lysozyme. J Chromatogr A. 2002;959:113–20.
Singh et al. Microbial Cell Factories  (2015) 14:41 Page 10 of 1083. Kweon DH, Lee DH, Han NS, Seo JH. Solid-phase refolding of cyclodextrin
glycosyltransferase adsorbed on cation-exchange resin. Biotechnol Prog.
2004;20:277–83.
84. Glynou K, Ioannou PC, Christopoulos TK. One-step purification and refolding
of recombinant photoprotein aequorin by immobilized metal-ion affinity
chromatography. Protein Expr Purif. 2003;27:384–90.
85. Yin SM, Zheng Y, Tien P. On-column purification and refolding of recombinant
bovine prion protein: using its octarepeat sequences as a natural affinity tag.
Protein Expr Purif. 2003;32:104–9.
86. Zahn R, von SC, Wuthrich K. Human prion proteins expressed in Escherichia coli
and purified by high-affinity column refolding. FEBS Lett. 1997;417:400–4.
87. Geng X, Chang X. High-performance hydrophobic interaction chromatography
as a tool for protein refolding. J Chromatogr A. 1992;599:185–94.
88. Ling M, Xu X, Shi F, Zhu Y, Long N. Refolding of recombinant human
interleukin-2 by reverse phase high performance liquid chromatography.
Chin J Biotechnol. 1997;13:180–3.
89. Jungbauer A, Kaar W, Schlegl R. Folding and refolding of proteins in
chromatographic beds. Curr Opin Biotechnol. 2004;15:487–94.
90. Li M, Su ZG, Janson JC. In vitro protein refolding by chromatographic
procedures. Protein Expr Purif. 2004;33:1–10.
91. Tsumoto K, Umetsu M, Yamada H, Ito T, Misawa S, Kumagai I. Immobilized
oxidoreductase as an additive for refolding inclusion bodies: application to
antibody fragments. Protein Eng. 2003;16:535–41.
92. Altamirano MM, Golbik R, Zahn R, Buckle AM, Fersht AR. Refolding
chromatography with immobilized mini-chaperones. Proc Natl Acad Sci U S
A. 1997;94:3576–8.
93. Dong XY, Yang H, Sun Y. Lysozyme refolding with immobilized GroEL
column chromatography. J Chromatogr A. 2000;878:197–204.
94. Dong XY, Yang H, Gan YR, Bai S, Sun Y. [Reactivation of denatured lysozyme
with immobilized molecular chaperones GroE]. Sheng Wu Gong Cheng Xue
Bao. 2000;16:169–72.
95. Altamirano MM, Garcia C, Possani LD, Fersht AR. Oxidative refolding
chromatography: folding of the scorpion toxin Cn5. Nat Biotechnol.
1999;17:187–91.
96. Chen Y, Susana SJL. High productivity refolding of an inclusion body
protein using pulsed-fed size exclusion chromatography. Process Biochem.
2010;45:1570–6.
97. Chen Y, Leong SS. Adsorptive refolding of a highly disulfide-bonded inclusion
body protein using anion-exchange chromatography. J Chromatogr A.
2009;1216:4877–86.
98. Yamaguchi H, Miyazaki M, Briones-Nagata MP, Maeda H. Refolding of
difficult-to-fold proteins by a gradual decrease of denaturant using
microfluidic chips. J Biochem. 2010;147:895–903.
99. Okada J, Maruyama T, Motomura K, Kuroki K, Maenaka K, Sakono M, et al.
Enzyme-mediated protein refolding. Chem Commun (Camb). 2009;46:7197–9.
100. Ou WB, Park YD, Zhou HM. Effect of osmolytes as folding aids on creatine
kinase refolding pathway. Int J Biochem Cell Biol. 2002;34:136–47.
101. Buchner J, Rudolph R. Renaturation, purification and characterization of
recombinant Fab-fragments produced in Escherichia coli. Biotechnology (N
Y). 1991;9:157–62.
102. Xia Y, Park YD, Mu H, Zhou HM, Wang XY, Meng FG. The protective effects
of osmolytes on arginine kinase unfolding and aggregation. Int J Biol
Macromol. 2007;40:437–43.
103. Samuel D, Kumar TK, Ganesh G, Jayaraman G, Yang PW, Chang MM, et al. Proline
inhibits aggregation during protein refolding. Protein Sci. 2000;9:344–52.
104. Kim SH, Yan YB, Zhou HM. Role of osmolytes as chemical chaperones
during the refolding of aminoacylase. Biochem Cell Biol. 2006;84:30–8.
105. Cleland JL, Wang DI. Cosolvent assisted protein refolding.
Biotechnology (N Y). 1990;8:1274–8.
106. Cleland JL, Builder SE, Swartz JR, Winkler M, Chang JY, Wang DI. Polyethylene
glycol enhanced protein refolding. Biotechnology (N Y). 1992;10:1013–9.
107. Wang F, Liu Y, Li J, Ma G, Su Z. On-column refolding of consensus interferon at
high concentration with guanidine-hydrochloride and polyethylene glycol
gradients. J Chromatogr A. 2006;1115:72–80.
108. Rahimpour F, Mamo G, Feyzi F, Maghsoudi S, Hatti-Kaul R. Optimizing
refolding and recovery of active recombinant Bacillus halodurans xylanase
in polymer-salt aqueous two-phase system using surface response analysis.
J Chromatogr A. 2007;1141:32–40.
109. Sawano H, Koumoto Y, Ohta K, Sasaki Y, Segawa S, Tachibana H. Efficient
in vitro folding of the three-disulfide derivatives of hen lysozyme in the
presence of glycerol. FEBS Lett. 1992;303:11–4.110. Majumder A, Basak S, Raha T, Chowdhury SP, Chattopadhyay D, Roy S. Effect of
osmolytes and chaperone-like action of P-protein on folding of nucleocapsid
protein of Chandipura virus. J Biol Chem. 2001;276:30948–55.
111. Vallejo LF, Rinas U. Optimized procedure for renaturation of recombinant human
bone morphogenetic protein-2 at high protein concentration. Biotechnol Bioeng.
2004;85:601–9.
112. Goldberg ME, Expert-Bezancon N, Vuillard L, Rabilloud T. Non-detergent
sulphobetaines: a new class of molecules that facilitate in vitro protein
renaturation. Fold Des. 1995;1:21–7.
113. Vicik SM. Methods of refolding proteins by use of zwitterionic low
molecular weight agents. 1999. WO 99/18196.
114. Vallejo LF, Brokelmann M, Marten S, Trappe S, Cabrera-Crespo J, Hoffmann
A, et al. Renaturation and purification of bone morphogenetic protein-2
produced as inclusion bodies in high-cell-density cultures of recombinant
Escherichia coli. J Biotechnol. 2002;94:185–94.
115. Shinde U, Inouye M. Intramolecular chaperones and protein folding. Trends
Biochem Sci. 1993;18:442–6.
116. Zhu XL, Ohta Y, Jordan F, Inouye M. Pro-sequence of subtilisin can guide
the refolding of denatured subtilisin in an intermolecular process. Nature.
1989;339:483–4.
117. Beer HD, Wohlfahrt G, Schmid RD, McCarthy JE. The folding and activity of
the extracellular lipase of Rhizopus oryzae are modulated by a prosequence.
Biochem J. 1996;319(Pt 2):351–9.
118. Tang B, Nirasawa S, Kitaoka M, Marie-Claire C, Hayashi K. General function of
N-terminal propeptide on assisting protein folding and inhibiting catalytic
activity based on observations with a chimeric thermolysin-like protease.
Biochem Biophys Res Commun. 2003;301:1093–8.
119. Rozema D, Gellman SH. Artificial chaperones: Protein refolding via
sequential use of detergent and cyclodextrin. J Am Chem Soc.
1995;117:2373–4.
120. Nath D, Rao M. Artificial chaperone mediated refolding of xylanase from an
alkalophilic thermophilic Bacillus sp. Implications for in vitro protein
renaturation via a folding intermediate. Eur J Biochem. 2001;268:5471–8.
121. Kuboi R, Morita S, Ota H, Umakoshi H. Protein refolding using stimuli-responsive
polymer-modified aqueous two-phase systems. J Chromatogr B Biomed Sci Appl.
2000;743:215–23.
122. Mondal K, Bohidar HB, Roy RP, Gupta MN. Alginate-chaperoned facile refolding
of Chromobacterium viscosum lipase. Biochim Biophys Acta. 2006;1764:877–86.
123. Huang Z, Leong SS. Molecular-assisted refolding: study of two different ionic
forms of recombinant human fibroblast growth factors. J Biotechnol.
2009;142:157–63.
124. Chen YJ, Huang LW, Chiu HC, Lin SC. Temperature-responsive polymer-assisted
protein refolding. Enzyme Microb Technol. 2003;32:120–30.
125. Middelberg AP. Preparative protein refolding. Trends Biotechnol.
2002;20:437–43.
126. Vallejo LF, Rinas U. Strategies for the recovery of active proteins through
refolding of bacterial inclusion body proteins. Microb Cell Fact. 2004;3:11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
